Fundraising FoxFlagship Pioneering — 2024 Investments
3 investments dated 2024 · listed companies and verified rows first · show all
Foghorn Therapeutics is a clinical-stage biotech developing chromatin-targeted cancer drugs via its Gene Traffic Control platform, including a candidate co-developed with Eli Lilly.
Adrian Gottschalk(President and Chief Executive Officer)
Co-investorsXeraya CapitalBiotechnology Value FundDeerfield Management Company
Inari applies artificial intelligence and gene editing to accelerate plant breeding, delivering crop improvement solutions for farmers focused on soybeans, corn, and wheat across broadacre agriculture.
AgTechAI & Machine LearningBiotechCambridge, US
Lisa Safarian(CEO)inStuart Brown(Chief Financial Officer)Pierre-Etienne Boin(Secretary and General Counsel)inPonsi Trivisvavet(President and Chief Executive Officer)inDavid Berry(Founder)
BoardRobert Berendes, Ph.D.(Director)
Co-investorsAcre Venture PartnersCongruent VenturesG SquaredCPP Investments
Prologue Medicines is a biotech company exploring the viral proteome using machine learning and next-generation sequencing to identify virus-evolved proteins and design programmable protein-based medicines.
AI & Machine LearningBiotechDeep Tech
Lovisa Afzelius(Co-founder & CEO)Theonie Anastassiadis(Founding President)Hozefa Bandukwala(Co-founder & Chief Innovation Officer)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.